量化炎症性肠病患者对新型双生物制剂治疗风险耐受的偏好
本研究基于炎症性肠病登记库,对280例经医生确诊且治疗失败或正在使用先进治疗的克罗恩病或溃疡性结肠炎患者开展离散选择实验,分析其对双生物制剂治疗疗效与风险的偏好。结果显示患者对双生物制剂治疗与单药治疗偏好无显著差异(P=0.25),强烈偏好避免糖皮质激素(P<0.001);为将缓解率从50%提高至70%,患者可接受最高17.5%(95%CI 17.0%-18.0%)的严重感染风险。
要点
- 患者对双生物制剂治疗与单药治疗的偏好无显著差异(P=0.25)。
- 患者强烈偏好避免使用糖皮质激素(P<0.001)。
- 为将缓解率从50%提高至70%,患者可接受最高17.5%的严重感染风险。
核心结论
- 患者偏好安全有效的治疗,双生物制剂治疗可能是先进治疗失败的炎症性肠病患者可接受的选择。
- 基于现有证据设计高效的离散选择实验有助于填补知识空白并改善炎症性肠病诊疗。
研究设计与样本
- 基于现有治疗偏好研究证据设计聚焦离散选择实验,测量对治疗类型、缓解概率和严重感染风险的偏好。
- 通过炎症性肠病登记库招募经医生确诊的克罗恩病或溃疡性结肠炎且治疗失败或正在使用先进治疗的患者。
- 采用全相关随机参数logit模型分析离散选择实验应答。
主要发现
- 共280名受访者完成离散选择实验调查,多数为白人、女性、曾因炎症性肠病住院并正在接受生物制剂单药治疗。
- 对双生物制剂治疗与单药治疗的偏好无有意义的差异(P=0.25)。
- 强烈偏好避免糖皮质激素(P<0.001)。
- 为将缓解概率从50%提高至70%,受访者可接受最高17.5%(95%CI 17.0%-18.0%)的严重感染风险。
关键数值与推荐
- 双生物制剂治疗与单药治疗偏好比较P=0.25。
- 避免糖皮质激素偏好P<0.001。
- 缓解概率从50%提高至70%时可接受严重感染风险最高17.5%(95%CI 17.0%-18.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Many patients with inflammatory bowel disease (IBD) experience treatment failures despite availability of effective advanced biologic and small-molecule therapies with differing mechanisms of action. Dual biologic therapy (DBT) is being explored to improve efficacy outcomes and address unmet needs in this difficult-to-treat population. This study aimed to understand patient preferences for DBT efficacy and risk tolerance. METHODS: Built on evidence from existing treatment-preference studies, a focused discrete-choice experiment (DCE) was developed to measure preferences for treatment type, chance of remission, and risk of serious infection. Individuals with a physician-verified diagnosis of Crohn's disease or ulcerative colitis who had failed or were taking advanced therapy were recruited through an IBD registry. DCE responses were analyzed using a fully correlated random parameters logit model. RESULTS: The DCE survey was completed by 280 respondents. The majority of respondents were White, female; had been previously hospitalized for IBD; and were receiving biologic monotherapy for their IBD disease. There was no meaningful difference in preference for DBT or monotherapy ( P = 0.25), while there was strong preference to avoid corticosteroids ( P < 0.001). To improve from a 50% to 70% in chance of remission, respondents would accept up to a 17.5% (95% confidence interval 17.0%-18.0%) risk of serious infection. DISCUSSION: The findings suggest that patients prefer safe and efficacious treatments and DBT may be an acceptable option for those who have failed an advanced therapy for IBD. We demonstrate the value of building on existing evidence and designing efficient DCE studies to address knowledge gaps to improve IBD care.
引用
- Yang JC, Janssen EM, Wallace MJ, et al. Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel Disease. Am J Gastroenterol. 2025. PMID: 40243385. doi:10.14309/ajg.0000000000003397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。